The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Jose A. Karam
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Other Remuneration - Pfizer
Catherine E Devine
No relevant relationships to disclose
Diana L Urbauer
No relevant relationships to disclose
Marisa Lozano
No relevant relationships to disclose
Kamran Ahrar
No relevant relationships to disclose
Pheroze Tamboli
No relevant relationships to disclose
Nizar M. Tannir
Research Funding - Pfizer
Christopher G. Wood
Honoraria - Pfizer
Research Funding - Pfizer
Other Remuneration - Pfizer